

COLLAGENIC PEPTIDES MODIFIED BY GRAFTING MERCAPTO
FUNCTIONS, PROCESS FOR OBTAINING THEM AND USES
THEREOF AS BIOMATERIALS

5 The present invention relates to novel collagenic
peptides chemically modified by grafting free or
substituted thiol functions, borne by mercaptoamino
residues. When the collagenic peptides comprise thiol
functions, they have the property of being crosslinkable
10 by oxidation and give a collagen derivative crosslinked
with disulfide bridges.

The invention is also directed toward a process for
preparing these novel collagen derivatives which are in
15 crosslinkable form, in the form of a crosslinkable
precursor of a derivative or in crosslinked form.

The invention also relates to the uses of these novel
collagenic peptides as biomaterials that are useful as
20 starting materials for the manufacture of medical,
surgical or cosmetic products, such as artificial tissues
or organs, artificial skin, bone, ligament,
cardiovascular, intraocular, intraperitoneal, etc.
prostheses or implants, or alternatively bioencapsulation
25 systems (implants, microspheres or microcapsules)
allowing the sustained and controlled release of active
principles in vivo. Medical accessories such as suture
threads and also biocompatibilizing coatings for
implantable medical articles are other illustrations of
30 the possible uses of the novel biomaterials according to
the invention.

For the purposes of the present invention, the term
"collagenic peptide" in particular denotes collagen with
or without telopeptides, denatured collagen and also
35 gelatin.

Various commercial grades of collagen, with or without telopeptides, are found on the market. These commercial collagens may be of human or animal origin. Collagen is a known protein, which is present at all the levels of organization of animal tissues: it is the main protein of the skin and of connective tissue. By nature, it has biochemical and physicochemical characteristics that are relatively well suited for uses as biomaterials. These characteristics are, in particular: good biocompatibility and biodegradability, hemostatic nature, etc.

However, it must be stated that collagen-based implantable medical, surgical or cosmetic articles suffer from certain shortcomings. They have poor mechanical characteristics, which makes them difficult to handle, or even makes them unusable for certain applications. Furthermore, their biodegradation may be too rapid when the implants need to exert palliative and/or curative functions for long periods. To improve the mechanical and biodegradation characteristics of collagen-based implants, it is found to be necessary to modify the collagen chemically, and in particular to crosslink it.

To modify, in particular to crosslink, collagenic peptides, the reactive functions present on the side chains of certain amino acids of collagen are used, namely:

- the amine functions of the lysine residues, representing in numerical terms 3% of the amino acids,
- the carboxylic acid functions of the aspartic acids and glutamic acids, representing in numerical terms 9% to 12% of the amino acids,
- the alcohol functions of the serine, threonine and hydroxyproline residues, representing in numerical terms 14% of the amino acids.

• Thus, four major technical types of artificial crosslinking of this collagenic peptide have appeared.

1. Creation of a network by covalent bonding between the collagen molecules, by irradiation or forced dehydration. This crosslinking is obtained without chemical functionalization of the collagen.
2. Activation of the natural groups of the collagen, to introduce the possibility of self-crosslinking, for example by oxidation (periodate) or by functional activation (activation of the acids with carbodiimides, in the form of azide ... which react with the amines).
3. Crosslinking with difunctional or polyfunctional bridging chemical agents (aldehydes, dicarboxylic compounds, diamines, diisocyanates, disulfonyl chlorides or difunctionalized polyethylene glycol).
4. Copolymerization by covalent bonding of the collagen with another polymer (polyacrylic, copolyacrylonitrile-styrene, polyurethane, polyalcohol or silicone).

One crosslinking variant of type 3. by bridging may consist in using difunctional derivatives containing disulfide groups. This variant is the one which is of interest in the context of the invention. Said variant has given rise in the prior art to various technical propositions, which will be presented below.

The article by F. Schade & H. Zahn [Einbau von cystinbrücken in Kollagen, Angew. Chem., 74, 904, 1962], describes the functionalization of collagen using a cystine derivative, by formation of amide bonds between, on the one hand, the free NH_2 moieties of the lysine residues of the collagenic chain and, on the other hand, the carboxyl moieties of the cystine derivative, which have been preactivated by esterification with

nitrophenol. The reduction of the disulfide bridges of the grafted cystine derivatives gives a thiolized material which is crosslinkable by oxidation. Since only the lysine residues of the collagen are functionalized, the maximum degree of functionalization, which is directly proportional to the level of crosslinking, is not more than 3% in numerical terms.

European patent application EP 0 049 469 discloses the functionalization of soluble collagen extracted from tendons using N-acetyl homocysteine thiolactone. This is also a case of a reaction between the carboxyl moieties of the functionalizing agent and the amine moieties of the lysine residues of the collagen. The maximum content of grafted thiol functions is thus in this case also not more than 3%.

In order to obtain novel thiolated collagenic derivatives and/or to increase the degrees of grafting of thiol functions on collagen and thereafter the level of crosslinking, the Applicant has proposed, in turn, three novel routes for chemical functionalization of collagen with groups bearing thiol functions or precursors thereof.

The first route is described in French patent FR 2 692 582 which concerns a collagen grafted with thiolated derivatives (cysteine, homocysteine or cysteamine):

- via a succinic rotule, one of the carboxyl ends of which has reacted with amine moieties of the lysine residues and with certain alcohol moieties of the serine, threonine and hydroxyproline residues of the collagen and the other carboxyl end of which has reacted with the amine moiety of the thiolated

derivative; and

- optionally directly without a rotule on the carboxyl functions of the aspartic acids and glutamic acids of the collagen.

5 Up to 29% functionalization of the amino acids of the collagen may thus be achieved.

10 The mercaptoamino functions - that is to say the thiolated derivatives - described in said French patent are attached directly or indirectly to the free NH_2 , OH and COOH functions of the collagen. Said patent does not disclose a collagenic peptide whose OH and NH_2 moieties are functionalized with functions other than mercaptoamino functions.

15 The second route is given in patent FR 2 699 184 which relates to a collagen grafted with thiolated derivatives (cysteine or homocysteine) attached directly to the amine moieties of the lysine residues and certain alcohol
20 moieties of the serine, threonine and hydroxyproline residues. In accordance with the invention described by said patent, the functionalizing agent (e.g. cystine) which is the precursor of the thiolated derivative grafted onto the collagen comprises an activated carboxyl
25 function, which reacts with the NH_2 functions of the lysines to form amides and with the OH functions of the serines, threonines and hydroxyprolines to form esters. This functionalizing agent also comprises a protected amine function, which cannot react with the carboxyls of
30 the aspartic acids and glutamic acids of the collagenic chain. The maximum degree of grafting which may be achieved by this method is 17%.

35 A third route for the chemical modification of collagen which was developed by the Applicant to provide such a

polymer with crosslinking functionality, is described in French patent FR 2 723 957. Said patent discloses a collagen grafted on the free amine moieties of its lysine residues with a thiolated derivative consisting of cysteine or homocysteine whose amine and thiol functions are protected with one and the same protecting group, the whole forming a thiazolidine moiety. The carboxylic acid of the thiazolidine derivative is activated to be able to react with the amine functions of the lysine residues. Consequently, the degree of grafting in this case is not more than 3%. The free carboxylic functions of the glutamic acids and aspartic acids of the collagenic chain are not substituted in the collagen according to said patent.

The collagens according to these three French patents allow the preparation of medical articles (gels, felts, films, etc.) with advantageous levels of crosslinking, that is to say advantageous mechanical and biodegradation characteristics. However, there is scope for their improvement.

Collagens substituted with groups which are not crosslinking functions and which are intended to give the collagen other properties, for example by modifying its solubility characteristics and/or its rheological characteristics and/or its biological characteristics, are moreover known. Thus, patent application PCT WO 90/05755 describes a collagen in which the amines of the lysine residues it comprises are substituted with a synthetic hydrophilic polymer chain and more particularly with monomethyl polyethylene glycol. This collagen-PEG is presented as having low immunogenicity and improved mechanical properties of elasticity and malleability.

Patent application PCT WO 94/01483 discloses a biologically inert, biocompatible conjugated polymer material, formed by a natural polymer such as collagen, linked via an ether bond to a synthetic hydrophilic polymer such as polyethylene glycol (PEG).

The modified collagens according to the prior art do not afford all the desired satisfaction, as regards their mechanical properties, their *in vivo* degradation kinetics and their biological characteristics. Moreover, the known collagens modified with free or substituted thiol functions still have scope for improvement, as regards controlling, by means of the degree of crosslinking, their mechanical and biological characteristics.

Finally, it would be advantageous for the crosslinkable forms of the known modified collagens to have solubility properties over a wide pH range, so as to make them easier to use, without this having a negative effect on their level of crosslinking.

In this prior art, one of the essential objectives of the invention is to provide novel collagens modified by grafting free or substituted thiol functions, these novel collagens needing to be capable of crosslinking in a sufficient and controlled manner, by forming intercatenary disulfide bridges.

Another essential objective of the invention is to provide novel collagens modified by grafting thiol functions and characterized by high degrees of grafting coexisting with good solubility over a wide pH range.

Another essential objective of the invention is to provide novel collagens modified by grafting thiol

functions, that are easy to use and to handle industrially.

5 Another essential objective of the invention is to provide novel collagens modified by grafting thiol functions, in which the reactive functions are not all mobilized by crosslinking, so as to allow the grafting of noncrosslinking functionalities.

10 Another essential objective of the invention is to provide novel crosslinkable collagens or crosslinkable collagen precursors that are mercapto-functionalized and able to be converted into gels, films or felts (e.g.) whose crosslinking density (and thus mechanical strength
15 and biodegradation) may be modified beforehand, so as to provide a varied range of starting materials which may be used in numerous applications as biomaterials.

20 Another essential objective of the invention is to provide a simple process for preparing a collagenic peptide modified by grafting free or substituted thiol functions borne by mercaptoamino residues.

25 The inventors have, to their credit, achieved all these objectives, among others, by revealing the fact that the carboxylic functions of the aspartic acids and glutamic acids of the collagenic chain should be favored, as sites for grafting mercaptoamino functions which are the source of the crosslinking properties by S-S bridging between
30 the collagenic chains.

Thus, the present invention relates, firstly, to a collagenic peptide modified by grafting free or substituted thiol functions, borne by mercaptoamino
35 residues, characterized in that these mercaptoamino

residues are identical to or different than each other and are exclusively grafted onto the aspartic acids and glutamic acids of the collagenic chain via amide bonds, and in that said modified collagenic peptide is soluble
5 in aqueous medium and/or in polar solvents.

The fact that the crosslinking functionalities are borne by the carboxylic residues of the aspartic acids and glutamic acids gives the collagenic peptide according to
10 the invention advantageous properties that are entirely unexpected in mechanical and biological terms. Specifically, this modified collagenic peptide can, since it is in reduced thiol form, be crosslinked in a controlled manner, achieving degrees of crosslinking
15 which afford it stability and also good mechanical properties and modifiable biodegradability. Furthermore, since the lysine residues are not involved in the grafting of the mercaptoamino residues, they may serve as sites of attachment for other groups and may afford the
20 product diverse and varied functionalities that are useful in the intended applications.

When the collagenic peptide corresponds to native collagen with or without telopeptide, the degree of functionalization with mercaptoamino residues may reach
25 9% to 12% in numerical terms, since this corresponds to the ratio of amino acids of aspartic acid or glutamic acid type constituting the collagen. Asparagines and glutamines whose amides are capable of being hydrolyzed to form the corresponding acid derivatives are
30 compatibilized in this ratio.

According to one advantageous characteristic of the invention, this high degree of grafting is not incompatible with high solubility of the crosslinkable (non-crosslinked) forms of the modified collagen, in aqueous
35 medium and/or in polar solvents and over a wide pH range.


This makes it very easy to use.

In order to be able to crosslink by disulfide bridging, the modified mercaptoamino functionalities according to the invention need to be in reduced form, that is to say in thiol form (-SH). It is thus when they are in this form that the modified collagenic peptides may be termed "crosslinkable". This term reflects the ability of the modified collagenic peptides to self-crosslink spontaneously in the presence of atmospheric oxygen, at ambient temperature and optionally in the presence of auxiliary agents such as oxidizing agents.

The mercaptoamino residues bearing crosslinking functions of free thiol type or precursors thereof in substituted thiol form are advantageously residues that are closely or remotely derived from cysteine or analogues thereof: cysteamine and homocysteine. It is interesting to note that these various mercaptoamino residues are of biological nature.


In the present specification, two types of monovalent mercaptoamino residues or grafts are distinguished, namely those bearing directly crosslinkable thiol functions and those bearing mercapto functions that are precursors of said thiol functions.

As regards the mercaptans that are thiol precursors, they define a *first subfamily* of modified collagenic peptides according to the invention characterized in that at least some of the mercaptoamino residues, grafted onto the carboxylic acids of the aspartic acids and glutamic acids, correspond to the general formula (I) below:





in which


- $x = 1$ or 2 ;
- $\text{R}^0 = \text{H}$ or CH_3 ;
- R^1 represents H or COOR^3 with R^3 corresponding to a hydrocarbon-based radical of aliphatic, aromatic or alicyclic type, preferably alkyl, alkenyl, aryl, aralkyl, alkylaryl, aralkenyl or alkenylaryl type and even more preferably of methyl or ethyl type;
- R^2 is an aliphatic and/or alicyclic and/or aromatic radical, preferably an alkyl or an acyl optionally containing sulfur and/or amino, and even more preferably R^2 corresponds to formula (II) below:



with y , R^0 and R^4 corresponding to the same definition as that given in the legend in formula (I) for x , R^0 and R^1 .

More specifically, the grafted mercaptoamino residues of these collagenic peptides, that are not immediately crosslinkable, are chosen from the group of monovalent radicals comprising:





These are grafts derived from cystine and thus comprising a disulfide bridge which may be reduced with known
 5 reducing agents such as mercaptans (mercaptoethanol, mercaptoacetic acid, mercaptoethylamine, benzyl mercaptan, thioresol, dithiothreitol, etc.) and/or reductive salts (NaBH_4 , Na_2SO_3 , etc.) and/or organic reducing agents (phosphine).


10 These novel modified collagenic intermediates according to this *first subfamily* are stable and soluble in water and more generally in aqueous medium and/or in polar solvents. In addition, they are readily purifiable and isolable, which makes them products that are practical
 15 for packaging, storage and use.

The *second subfamily* of modified collagenic peptides according to the invention combines those in which the carboxyls of the glutamic acids and aspartic acids have
 20 reacted with the amine functions of the mercaptoamino residues of formula (I) in which the substituent R^2 corresponds to hydrogen.

The modified collagenic peptides according to the *second subfamily* may be prepared by reducing the collagenic
 25 peptides according to the *first subfamily*, using reducing agents such as those defined above.

These reduced collagenic peptides are readily purifiable and isolable. Since they are obtained in dry form after an isolation in acidic medium, these peptides are stable.
 30 Finally, they are soluble in water and more generally in aqueous medium and/or in polar solvents and are easy to use.

The mercaptoamino residues of these peptides containing free thiol functions are defined by formula (I') below:



in which R^1 may correspond to H or $COOR^3$, with x, R^1 , R^0 and R^3 as defined above, and also R^3 may represent hydrogen or a cation to form a salt with COO^- , this cation preferably being Na^+ , K^+ or Li^+ , when a step of deprotection of the ester is provided. The graft thus used is derived directly from cysteine.

Collagenic peptides comprising such mercaptoamino residues containing thiol reactive functions have the characteristic of being crosslinkable within the meaning of the invention.

The crosslinking is carried out by oxidizing the thiols to disulfide bridges, which makes it possible to obtain a chemically crosslinked three-dimensional collagenic network, which is insoluble in physiological media and entirely stable. This oxidation may be obtained, for example, with atmospheric oxygen in weakly basic medium, with aqueous hydrogen peroxide solution or with iodo derivatives (iodine, betadine).

Among the modified collagenic peptides in accordance with the invention, it is possible to isolate those which exist in crosslinked form and which compose a *third subfamily* of collagenic peptides comprising collagenic chains linked together via disulfide bridges, in which the constituent sulfur atoms belong to mercaptoamino residues grafted onto the aspartic acids and glutamic acids of the collagenic chains, exclusively via amide bonds.

These crosslinked collagenic peptides of the *third subfamily* may be advantageously obtained from the modified collagenic peptides of the *second subfamily*.


These crosslinked collagenic peptides are novel, stable products whose mechanical and biological qualities make them biomaterials of choice for producing medical or surgical articles such as implants, prostheses, dressings or artificial skin. Since it is possible to vary the degree of substitution of the carboxylic moieties of the aspartic acids and glutamic acids, there is certain room for maneuver in choosing the appropriate mechanical quality and the appropriate rate of biodegradation.

Moreover, the crosslinked form which is of concern for these collagenic peptides belonging to the *third subfamily* described in the present specification, is reversible. Specifically, it is possible to reduce the disulfide bridges using suitable reducing agents. Examples of these reducing agents are given above.

In accordance with the invention, the free carboxylic residues of the aspartic acid and glutamic acid monomers of the collagenic chain are mobilized for the grafting of crosslinking functionalities. However, the fact nevertheless remains that at least some of the other free functions of the collagenic chain, such as, for example, the amine functions of the lysine residues, may serve as sites of attachment for groups other than the mercaptoamino residues as defined above and which afford diverse and varied functionalities, that are useful in the intended applications.

As a result, the collagenic peptides as defined above may comprise, according to one variant, grafts G attached to at least some of the free amine moieties of the collagenic chain, via amide bonds, G being an acyl comprising a hydrocarbon-based species, WITH THE EXCLUSION of the mercaptoamino residues, in particular

those as defined above, this species optionally comprising hetero atoms (advantageously O and/or N) and preferably being chosen from alkyls and/or alkenyls and/or alicyclics and/or aromatics and even more preferably from groups comprising an optionally unsaturated alkyl chain, containing from 1 to 22 carbon(s) or corresponding to the formula (III) below:



with

- $\text{R}^5 = \text{H}$ or CH_3 ;
- $\text{R}^6 = \text{H}$ or a linear or branched alkyl radical and preferably a methyl;
- $z = 0, 1$ or 2 and $n > 0$.

The number of repeating units n is chosen such that the molecular weight of the polymer chain is between 100 and 15 000, preferably between 200 and 8 000, and is, for example, about 4 000.

This additional functionalization on the amine sites of the lysines may give the modified collagenic peptide a hydrophilic or hydrophobic nature, or even a surfactant nature, which allows the swelling, mechanical strength and degradation kinetics properties to be modified. It is also conceivable for this functionalization to have therapeutic aims by means of the attachment of an active principle.

In addition to the collagenic product aspect taken as such, the present invention also relates to the production of modified collagenic peptides, and in particular those as defined above and even more particularly those belonging to the *three subfamilies*

presented above.

5 The invention thus relates to a process for obtaining a
collagenic peptide modified by grafting free or
substituted thiol functions borne by mercaptoamino
residues. This process consists essentially in reacting
the collagenic peptide in solution with at least one
precursor of a mercaptoamino residue in which the thiol
function and the possible carboxylic function are
10 blocked, in the presence of at least one grafting agent
preferably chosen from the group of products for
activating carboxylic groups and even more preferably
from carbodiimides.

15 The production conditions are chosen such that the
grafting of the mercaptoamino residue is carried out on
the free carboxylic moieties of the aspartic acids and
glutamic acids of the collagenic chain.

20 This process is particularly novel and advantageous in
that it can be performed in aqueous medium in which the
starting materials and/or the intermediate products
and/or the final modified collagens are at least
partially dissolved.

25 In practice, all the products contained in the aqueous
reaction medium are dissolved therein, from the first to
the last step.

30 This synthesis in aqueous medium, in accordance with the
invention, is particularly advantageous industrially,
since it is very simple to carry out, inexpensive and
nonpolluting. Specifically, it is easy, for example, to
remove the reagents (e.g. by diafiltration) and to
35 recover the targeted modified collagen.

The process according to the invention is all the more advantageous since it makes it possible to achieve high degrees of grafting of mercaptoamino residues (e.g. 12%).

5 Preferably, the mercaptoamino residues (monovalent groups) which are grafted onto the collagenic peptide are those as defined above, in particular in formulae (I), (I.1), (I.2) and (I.3).

10 In practice, the collagenic peptides thus obtained correspond, for example, to the precursors as targeted above, of crosslinkable collagenic peptides.

These precursors are included in the *first subfamily* of modified collagenic peptides according to the invention.

15 In order to be able to react with the free carboxylic moieties of the collagenic peptide, the mercaptoamino graft has a free amine function capable of reacting with the COOHs to form an amide bond. This precursor is, for
20 example, a cysteine, a homocysteine or a cysteamine in which the thiol function and the possible carboxylic acid function is (are) correctly protected. An efficient means for protecting the thiol function is to choose as precursor for the mercaptoamino residue to be grafted,
25 cystine, homocystine or cystamine, which comprise a disulfide bridge that stabilizes the mercapto function. Another means for protecting said function which may be chosen is any conventional function for protecting thiols
30 "Greene: *Protecting Groups in Organic Chemistry*, Wiley, 1975").

The possible COOH functions of the graft may themselves be protected with a protecting group or any other organic
35 function which may provide an advantageous property of

any nature (PEGs or hydrophobic or hydrophilic or charged groups).

5 According to one advantageous arrangement of the invention, the precursor of the mercaptoamino residue corresponds to a formula (IV) corresponding to formula (I) given above and in which the free valency is replaced with a substituent capable of reacting with the
10 carboxylic functions of the aspartic acids and glutamic acids of the collagenic chain, this substituent preferably being hydrogen, such that the reactive function is a primary amine. The precursors of formula (IV) that are most especially preferred are cystamine (I.1), cystine dimethyl ester (I.2) and cystine diethyl
15 ester (I.3), all three of which comprise a disulfide bridge that protects the thiol function.

In practice, the grafting of the mercaptoamino residue is carried out by dissolving the collagenic peptide and then
20 the precursor of the mercaptoamino residue to be grafted in a suitable solvent. This solvent may be, for example, water (preferably) and/or an organic solvent, for instance dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) or the like.

25 The reaction conditions are chosen so as to prevent the activated collagen from reacting with the amines contained in its own skeleton.

A coupling agent, such as a carbodiimide, is then added
30 to the reaction solution and the grafting is left to proceed while stirring the medium for a few hours, at ambient temperature.

The process according to the invention makes it possible
35 to obtain collagenic peptides substituted with

mercaptoamino residues that are precursors of the crosslinkable thiol residues. The peptides thus obtained are novel intermediate products that are stable and soluble in water. They may be isolated and purified, for example by dialysis or diafiltration and then lyophilization or by precipitation in organic medium and then drying.

A subject of the present invention is also a process for preparing a crosslinkable collagenic peptide modified by grafting free thiol functions borne by mercaptoamino residues. This process is characterized in that it consists essentially:

1. in reacting in solution the collagenic peptide with at least one precursor of a mercaptoamino residue whose thiol function and possible carboxylic function are blocked, in the presence of at least one grafting agent preferably chosen from the group comprising products that activate carboxylic groups, preferably carbodiimides,
2. and in deprotecting (conversion to thiols) the mercapto functions of the mercaptoamino residues grafted onto the modified collagenic peptides obtained in step 1.

The crosslinkable collagenic peptides thus prepared correspond, for example to the products containing free thiol functions included in the *second subfamily* of modified collagenic peptides, as defined above.

When the protection or masking of the mercapto functions is provided by a disulfide bridge (that is to say when the graft precursors are, for example, cystamine or cystine), the thiol function is regenerated by reduction.

This reduction may be carried out using reducing agents such as mercaptans (mercaptoethanol, mercaptoacetic acid, mercaptoethylamine, benzyl mercaptan, thiocresol, dithiothreitol, etc.) and/or reductive salts (NaBH_4 , Na_2SO_3 , etc.) and/or organic reducing agents (phosphine).

According to one preferred characteristic of the present invention, the protective disulfide bridge is reduced in basic aqueous medium using dithiothreitol. After this step, the thiolated collagen obtained is purified by dialysis/diafiltration and may be isolated, for example by lyophilization.


The invention also relates to a process for preparing a crosslinked collagenic peptide, from a collagenic peptide modified by grafting free thiol functions borne by mercaptoamino residues. This process is characterized in that it consists, essentially:

1. in reacting in solution the collagenic peptide with at least one precursor of a mercaptoamino residue whose thiol function and possible carboxylic function are blocked, in the presence of at least one grafting agent preferably chosen from the group comprising products that activate carboxylic groups, preferably carbodiimides,
2. and in deprotecting (conversion to thiols) the mercapto functions of the mercaptoamino residues grafted onto the modified collagenic peptides obtained in step 1,
3. and in oxidizing the thiol functions of the crosslinkable modified collagenic peptide obtained in step 2, so as to form intercatenary disulfide bridges.

This oxidation may be carried out, for example, using atmospheric oxygen in weakly basic medium, or using aqueous hydrogen peroxide solution or iodo derivatives (iodine, betadine).

5 The crosslinked collagenic peptides, as prepared by the above process, correspond in particular to the crosslinked products of the *third subfamily* of modified collagenic peptides as defined above.

10 According to one advantageous characteristic which is intrinsic to the three processes described above, an additional step F is envisaged, this being a step of functionalization with grafts G that are different in nature from the grafts attached to the carboxylic
15 functions of the aspartic acids and glutamic acids, this step F consisting essentially in carrying out an acylation of at least some of the free amine functions of the collagenic chain, so as to attach thereto grafts G comprising a hydrocarbon-based species, WITH THE
20 EXCLUSION of mercaptoamino residues, in particular those as defined above, this species optionally comprising hetero atoms (advantageously O and/or N) and preferably being chosen from alkyls and/or alkenyls and/or alicyclics and/or aromatics, and even more preferably
25 from groups comprising an optionally unsaturated alkyl chain or corresponding to formula (III) below:



with:

- $R^5 = H$ or CH_3 ;
- 30 • $R^6 = H$ or a linear or branched alkyl radical and preferably a methyl;
- $z = 0, 1$ or 2 and $n > 0$.

In order to be able to react by acylation with the three amine functions of the residue of the collagenic chain, the precursors of the grafts G advantageously comprise at least one activatable carboxylic acid function.

5

It is preferable for this acylation to proceed before the reaction of the free carboxylic functions of the collagenic chain with the precursor of the mercaptoamino graft (I). Having said this, it is not excluded for this acylation also to take place on the thiolated collagenic peptides obtained from step 1 and/or on the crosslinked collagenic peptides obtained from step 3 (e.g. directly on a crosslinked film, with removal of the reagents by simple washing).

15

The acylation and coupling reactions of amine functions with carboxylic sites belonging to proteins are known to those skilled in the field of protein biochemistry. For further details in this respect, reference will be made in particular to the following books:

20

- *"Techniques in protein chemistry"* R.L. Lundblad Chap. 10-14.
- *"Chemistry of protein conjugation and cross-linking"* S.S. Wong, Boca raton, CRC Press, 1993, Chap. 2.

25

It is interesting to note that the reagents used for the chemical modifications performed according to the processes in accordance with the invention are either convertible into nontoxic products or readily removable by nondegrading processes such as, for example, dialysis.

30

Moreover, the invention offers the very appreciable possibility of controlling the kinetics and the degree of crosslinking of the collagen.

35

Another appreciable advantage of the present invention is that it allows the mechanical and biodegradation properties to be modified by controlling the number of mercaptoamino residues introduced per unit of mass of the collagen.

It is also interesting to be able to functionalize the crosslinked or noncrosslinked collagenic chains with hydrophilic functions, for example.

Finally, it is important to point out that the products according to the invention may be sterilized by the conventional methods for sterilizing biological polymers.

Finally, the very good solubility of the novel noncrosslinked collagenic peptides according to the invention in aqueous medium must be stressed, these peptides having the characteristic of containing sulfur-containing crosslinking functions borne exclusively by the carboxyls of the aspartic acids and glutamic acids.

As a result, the crosslinkable products according to the invention find immediate applications firstly in human medicine and secondly in the field of biology.

In human medicine, they may implants, for ophthalmological implants, prostheses (for example bone prostheses), dressings in the form of films or felts, artificial tissues (epidermis, blood vessels, ligaments or bone), bioencapsulation systems (microspheres or microcapsules) allowing the controlled release of active principles in vivo, biocompatibilizing coatings for implantable medical articles, or suture threads. The crosslinkable collagenic products according to the invention may also be used in surgery, as adhesives

and/or as sealing materials (cements).

In biology, the materials according to the invention constitute excellent supports for two-dimensional cell cultures (films) and three-dimensional cell cultures (felts).

The crosslinked collagen according to the invention may be used alone or as a mixture, for example with modified or unmodified biological polymers or synthetic polymers.

For each of the abovementioned biomedical applications, it is essential to have available a crosslinked collagen which has determined and specific physicochemical, mechanical or biological properties. Consequently, it is necessary to control fully the chemical modifications of the collagen, so as to be able to produce a wide range of crosslinkable collagens and thus to satisfy most of the constraints appearing during the development of the specifications for a given application. It emerges from the above description that the invention fully satisfies this need.

Other advantages and variants of the present invention will emerge clearly from the implementation examples given below.

EXAMPLES

EXAMPLE 1: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd SUBFAMILY) IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION REPRESENTING 0.8% OF THE AMINO ACIDS)

1) *Step I: coupling (production of 1st subfamily):*

25 g of atelocollagen (types I + III, extracted from calf skins, 1.3 mmol of COOH/g) are placed in 2.5 l of water and the temperature of the medium is raised to 50°C with stirring. The 1% w/v solution thus obtained is filtered through a 0.22 µm filter.

Once the temperature has fallen to 30°C, 46.5 g of cystine diethyl ester are added and the pH is adjusted to 4.2. 0.6 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl is then added and the reaction is left to proceed for 2 h at 30°C with stirring. The reaction medium is concentrated to 5% w/v and dialyzed against water to remove the excess reagents and the reaction byproducts.

The product obtained is a stable synthetic intermediate. It is a collagenic peptide (1st subfamily) a fraction of the aspartic acids and glutamic acids of which are substituted with cystine diethyl ester.

The degree of substitution is measured by assaying with NSTB (2-nitro-5-thiosulfobenzoate), a reagent for disulfide bridges. This assay is described in: Thannhauser T.W. et al., Analysis of disulfide bonds in peptides and proteins. *Methods in Enzymology*. Jacoby W.B. and Griffith O. XL New-York: Academic Press, 1987. Vol. 143, 115-119.

[S-S]: 0.094 mmol/g of dry product; i.e. 0.87 mol% of substituted amino acids.

The product obtained may be isolated by lyophilization or may be reduced to give the corresponding thiol collagen.

2) Step II: reduction (production of 2nd subfamily):

7.6 g of glycine, 5.8 g of 1,4-dithiothreitol and a sufficient amount of 4N NaOH to reach a pH of 9.0 are added to the modified collagenic peptide dissolved at 5%

w/v in water, obtained in step I. The reaction medium is stirred for three hours at 35°C. At this stage, the solution is acidified to pH 2 with 6N HCl, dialyzed against 0.012N HCl to remove all trace of reagents and of reaction byproducts and then filtered through a 0.22 μ m filter. The product thus purified is isolated by lyophilization.

The degree of substitution is measured by an assay with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB), a reagent which is specific for thiol functions. This assay is described in: "Ellman G.L., Tissue sulfhydryl groups, *Archives of Biochemistry and Biophysics*, 1959, 82, 70-77".

[SH]: 0.091 mmol/g of dry product, i.e. 0.8 mol% of substituted amino acids.

The entire synthesis may be performed aseptically so as to obtain *in fine* the product in the form of a sterile lyophilizate.

EXAMPLE 2: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd SUBFAMILY) IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION REPRESENTING 3 MOL% OF THE AMINO ACIDS)

Example 1 is repeated, the only difference being that the amount of coupling agent is 2.9 g.

[SH]: 0.347 mmol/g of dry product, i.e. 3.3 mol% of substituted amino acids.

EXAMPLE 3: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd SUBFAMILY) IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION REPRESENTING 7 MOL% OF THE AMINO ACIDS)

Example 1 is repeated, the only difference being that the amount of coupling agent is 12 g.

[SH]: 0.706 mmol/g of dry product, i.e. 7 mol% of substituted amino acids.

EXAMPLE 4: SYNTHESIS OF A GELATIN (2nd SUBFAMILY) IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION REPRESENTING 5 MOL% OF THE AMINO ACIDS)

Example 1 is repeated, replacing the atelocollagen with gelatin (gelatin extracted from pig skins, 250 bloom, 1 mmol of COOH/g).

[SH]: 0.536 mmol/g of dry product, i.e. 5.2 mol% of substituted amino acids.

EXAMPLE 5: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd SUBFAMILY) IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEAMINE (DEGREE OF SUBSTITUTION REPRESENTING 3 MOL% OF THE AMINO ACIDS)

Example 1 is repeated, replacing 46.5 g of cystine diethyl ester with 28.4 of cystamine.

[SH]: 0.33 mmol/g of dry product, i.e. 3.0 mol% of substituted amino acids.

EXAMPLE 6: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd SUBFAMILY) IN WHICH THE AMINES ARE ACETYLATED (GRAFT G) AND IN WHICH THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION REPRESENTING 5 MOL% OF THE AMINO ACIDS)

25 g of atelocollagen (types I + III, extracted from calf
skins, 1.0 mmol of COOH/g; 0.33 mol of ϵ -NH₂/g) are placed
in 0.5 l of water and the temperature of the medium is
5 raised to 50°C with stirring. The 5% w/v solution thus
obtained is filtered through a 0.22 μ m filter.

After cooling the solution to 30°C, 4.2 g of NaHCO₃ and a
sufficient quantity of 4N NaOH to adjust the pH to 8.5
are dissolved. 7.34 ml of acetic anhydride are then added
10 slowly and sequentially, over 30 minutes with stirring at
30°C, while maintaining the pH at 8.5 with 4N sodium
hydroxide solution. The solution is then acidified slowly
to pH 3 with 6N HCl and is dialyzed against water to
remove the excess reagents. Finally, the 1% w/v medium is
15 diluted with water and the synthesis is continued as
described in Example 1 (coupling of cystine diethyl ester
followed by reduction).

[acetyl] by assay of acetic acid (Boehringer kit) after
basic hydrolysis of the product: 0.30 mmol/g of dry
20 product, i.e. 2.9 mol% of acetylated amino acids
(virtually total acetylation of the lysine residues).

[SH]: 0.53 mmol/g of product, i.e. 5.1 mol% of
substituted amino acids.

25 **EXAMPLE 7: SYNTHESIS OF A COLLAGENIC PEPTIDE (2nd
SUBFAMILY) IN WHICH THE AMINES ARE
SUBSTITUTED WITH PEG (GRAFT G) AND IN WHICH
THE CARBOXYLIC ACIDS ARE SUBSTITUTED WITH
CYSTEINE ETHYL ESTER (DEGREE OF SUBSTITUTION
30 REPRESENTING 5 MOL% OF THE AMINO ACIDS)**

10 g of atelocollagen (types I + III, extracted from calf
skins, 1.3 mmol of COOH/g; 0.33 mol of ϵ -NH₂/g) are placed
in 0.5 l of water and the temperature of the medium is
35 raised to 50°C with stirring. The 2% w/v solution thus

obtained is filtered through a 0.22 μ m filter.

Once the temperature has fallen to 30°C, the pH is adjusted to 9.0 with 4N NaOH. 5 g of methoxypolyethylene glycol propionic acid N-hydroxysuccinimidyl ester (SPA-PEG) of MW 5 000 g/mol are then added and the reaction is left to proceed at 30°C with stirring for 30 min, while maintaining the pH at 9 by adding 4N NaOH. A further 5 g of SPA-PEG are added and the reaction medium is stirred for 30 min while maintaining the pH. The medium is then diluted to 1/2 with water to bring the collagen concentration to 1% w/v.

18.5 g of cystine diethyl ester are added and the pH is adjusted to 4.2. 2.2 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCL are then added and the reaction is left to proceed for 2 h at 30°C with stirring. The reaction medium is concentrated to 5% w/v and dialyzed against water to remove the excess reagents and the reaction byproducts.

3.0 g of glycine, 2.3 g of 1,4-dithiothreitol and a sufficient quantity of 4N NaOH to reach a pH of 9.0 are added to the modified collagenic peptide dissolved at 5% w/v in water. The reaction medium is stirred for 3 hours at 35°C. At this stage, the solution is acidified to pH 2 with 6N HCl, dialyzed against 0.012 N HCl to remove all trace of reagents and reaction byproducts and then filtered through a 0.22 μ m filter. The product thus purified is isolated by lyophilization.

The lyophilizate is extracted with 2 l of absolute ethanol, contracted with acetone and then dried under vacuum at 30°C for 18 h.

The absence of ungrafted polyethylene glycol is monitored by gel permeation chromatography, with refractometric detection.

[SH]: 0.247 mmol/g of dry product, i.e. 4.5 mol% of substitution of the amino acids.

[PEG]: 0.8 mol% substitution of the amino acids, degree recalculated according to the amount of OH-proline assayed in the modified product/unmodified product.

EXAMPLE 8: SOLUBILITY OF THE MODIFIED COLLAGENIC PEPTIDES

250 mg of the collagenic peptide are placed in 5 g of water for injection and are stirred in a sealed flask for 15 min at 40°C. The pH measurements are carried out at 30°C. The pH adjustments are carried out using 1N NaOH. A number of solubility examples are given in Table 1.

TABLE 1:

COLLAGENIC PEPTIDE OBTAINED	INITIAL APPEARANCE	SOLUBILITY
Example 1	pH 2.1 clear solution	no region of insolubility for a pH ranging from 2.5 to 10
Example 3	pH 2.2 clear solution	no region of insolubility for a pH ranging from 2.5 to 10
Example 5	pH 1.9 clear solution	no region of insolubility for a pH ranging from 2.5 to 10
Example 7	pH 2.5 transparent gel	gradual fluidization as the pH is increased. Fluid solution at and above pH 6

EXAMPLE 9: CROSSLINKING OF THE COLLAGENIC PEPTIDES (2nd SUBFAMILY) BY OXIDATION: FORMATION OF GELS (3rd SUBFAMILY)

The process used is the same irrespective of the collagenic peptide used (Examples 1, 3 and 7).

/

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
22

250 mg of lyophilizate are placed in 4.5 ml of 10 mM pH 7.4 phosphate-buffered saline (PBS) and the mixture is stirred in a sealed flask at 40°C for 15 minutes. The pH is adjusted to 7.4 ± 0.1 with 1N NaOH and the amount of PBS required to obtain a final collagenic peptide concentration of 50 g/l is added. The samples are placed at 37°C. 100 μ l of a 1% H₂O₂ solution in PBS preheated to 37°C are added to 900 μ l of the collagenic peptide solution. The indications of Table 2 show that the crosslinking by oxidation (kinetics and degree), under given conditions, depends on the modified collagenic peptide used.

TABLE 2

COLLAGENIC PEPTIDE OBTAINED	SETTING TIME OF THE GEL (37°C)	DESCRIPTION OF THE GEL (37°C)
Example 1	20 seconds	soft transparent homogeneous gel
Example 3	5-10 seconds	turbid homogeneous gel
Example 7	1 minute 15 seconds	soft and sticky transparent homogeneous gel

EXAMPLE 10: CROSSLINKING OF THE COLLAGENIC PEPTIDES BY OXIDATION: FORMATION OF FILMS

The process for preparing the film is identical irrespective of the collagenic peptide used.

Step 1:

A solution containing 20 g/l of precursor collagenic peptide is prepared by dissolving lyophilizate in sterile water. In this example, 2.0 g of lyophilizate are

dissolved in 98 g of sterile water. The mixture is stirred in a sealed container at 40°C for 15 min in order to obtain complete dissolution. The pH of the solution is adjusted to 6.5 with 1N sodium hydroxide solution, at 25°C. The solution is stirred again at 40°C for 10 min.

Step 2:

The solution at 40°C is filtered through membranes of porosity 0.45 μm and then membranes of porosity 0.2 μm . The final filtration is carried out over sterile molds (polystyrene Petri dishes may be used).

Step 3:

40.0 g of filtered solution are run into two 12 \times 12 cm^2 molds. The molds are closed.

Step 4:

The solution is matured, which is reflected by a physical gelation, for 24 h at a temperature of $16^\circ\text{C} \pm 1^\circ\text{C}$. This temperature is necessarily less than the gel/sol transition temperature. The maturation is carried out in a chamber at controlled temperature, and the molds rest on a horizontal plate.

Step 5:

After 24 h, the mold covers are removed and the gelled solutions are evaporated over 24 h, at the same temperature in a confined chamber, in the presence of desiccants (typically sodium hydroxide pellets). After 24 h, the films obtained are dry, clear and smooth.

Step 6:

The dry films are crosslinked at 20°C, by adding 30 g of 0.3% hydrogen peroxide solution in an aqueous decimolar solution of ammonium acetate.

Step 7:

The crosslinked film is removed and washed successively with 30 g of pH 7.4 phosphate buffer and 30 g of water. All the solutions used are sterile.

Step 8:

The film is then left to dry under a laminar flow fume cupboard for 24 h. The dried films obtained contain a residual percentage of water of about 10%.

The films obtained are stable at room temperature. They remain stable and manipulable after 24 h in water or in a phosphate buffer.

EXAMPLE 11: TENSILE MECHANICAL PROPERTIES OF THE FILMS OBTAINED ACCORDING TO EXAMPLE 10

The measurements of the mechanical properties of the films are carried out using a universal testing machine of DY34 type of the brand Adamel Lhomargy. The films are hydrated at ambient temperature in a phosphate buffered saline (PBS, pH = 7.4) for 2 h. Next, they are cut into 4 mm by 30 mm strips using a very sharp sample punch. The thickness is measured on the hydrated samples. The samples are mounted on a cardboard frame which helps to position them in the jaws. The sample of film is kept hydrated. The frame is cut just before the tensile test, which proceeds at a constant speed of 2 mm/min. The initial modulus and the breaking stress are calculated from the tensile curves using the sections of hydrated test pieces.

The tensile properties of the films obtained according to the process described in Example 10 depend on the modified collagenic peptide used, as shown in Table 3.

TABLE 3:

COLLAGEN I C PEPTIDE OBTAINED	DRY THICKNESS (μM)	WET THICKNESS (μM)	FMAX (N)	ELONGATION (%)	σ max (Mpa)	INITIAL MODULUS (MPa)
Example 1	45	153	2.9	43	3.2	4.6
Example 2	45	94.5	3.1	28.5	8.1	21.6
Example 3	45	80	5.4	42.5	16.7	25.8

LEGEND: Fmax = maximum force at break

σ max = maximum breaking stress